Vertically Integrated Company Developing Science-Driven Cannabinoid Biopharmaceuticals
Developing science-driven synthetic cannabinoid therapies while driving innovation in the endocannabinoid space
NEW CLIENT ALERT!
AGORACOM Welcomes Blockchain Foundry A Leading North American, Revenue Generating Blockchain Development Firm
2020 H1 Revenue Of ~$900,000
- 187% Year Over Year Growth
- Positive Net Income
- Self sustaining consulting practice with growing pipeline and potential upside from product development and commercialization
- Partnered with Binance, the largest digital asset trading platform in the world, to leverage the Syscoin platform.
- A Blockchain company with Real Products, Real Customers, Real Revenues and Real Income
Blockchain Foundry is a “Blockchain 2.0” company that has survived and will thrive
Dr. Raymond W. Urbanski MD, PhD
Chief Executive Officer
Dr. Urbanski joins Applied BioSciences with an impressive list of accomplishments throughout his career ranging from academic research and private practice to his work and rise within the pharmaceutical industry. Dr. Urbanski spent eight years with Pfizer and held several positions within the company which included medical director of diversified products, senior medical director of breast cancer products, senior medical director of oncology clinical R&D, and eventually Vice President/Chief Medical Officer of the Established Products Business Unit. In addition to his roles with Pfizer, Dr. Urbanski served as Chief Medical Officer of Mylan Inc., Chief Medical Officer of MannKind Corp., and Senior Director of US Medical Affairs for Aventis.
Chris been an entrepreneur and operator for over 15 years. Most recently he founded Vessix, a flexible B2B payment solution provider for the aviation industry. Vessix was accepted into a tech accelerator (LaunchPad LA) at the end of 2012. In 2013 the company from Colorado to Los Angeles and began operations. Vessix is an FBO Management/POS platform + virtual credit card issuing business in private aviation. Vessix built a SaaS software platform, pilot app for making virtual card payments to vendors. Previously he worked at PRS Assets and Merrill Lynch.
Dr James Mulé
Dr. Mulé is Associate Center Director, the U.S. Senator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Dr. Mulé serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, KB Capital Management, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Dr. Mulé received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch , Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Al to, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endo wed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.
Professor Oded Shoseyov
Professor Oded Shoseyov is a Co-Founder of SP Nano Ltd. and serves as its Scientific Advisor. Prof. Shoseyov is the Scientific Founder of CBD Technologies., FuturaGene, Melodea and Bondex. He founded Collplant Holdings Ltd. in 2004 and has been its Chief Scientist Officer since August 2008. He serves as the Chief Scientist at CBD Technologies Ltd. Prof. Shoseyov He is a Founder of Fulcrum SP Ltd. Prof. Shoseyov is a Faculty Member of the Institute of Plant Science and Genetics in Agriculture and the Otto Warburg Center for Agricultural Biotechnology at the Faculty of Agriculture, Food and Environmental Quality Sciences of the Hebrew University of Jerusalem. His main field of research is plant molecular biology and biotechnology. He has extensive experience with genetic engineering of plants, protein engineering and nano-biotechnology. He serves as a Member of Advisory Board at EQUI-nom Ltd. Prof. Shoseyov serves as a Member of Scientific Advisory Board of FuturaGene Plc (now known as FuturaGene, LTD.). He served as a Director of Collplant Holdings Ltd. from May 20, 2010 to October 2016. He is an invited Speaker at many scientific conferences and has published extensively. He is the Inventor Or Co-inventor of more than 14 patents, 9 of which relate directly to CBD Technologies business. He has authored or co-authored more than 160 scientific publications and is the inventor or co-inventor of 42 patents. He has received numerous awards and appointments for his research in agricultural biotechnology. Prof. Shoseyov received the Outstanding Scientist Polak Award for 2002 and the 1999 Kay Award for Innovative and Applied Research. He received his B.S. with Excellence in 1981, his M.S. with Excellence in 1983 and his Ph.D. summa cum laude in 1988 from the Hebrew University of Jerusalem.
Patricia Reggio, Ph.D.
Scientific Advisory Board
Dr. Reggio brings over 30 years of active research in the endocannabinoid field with support from the National Institute on Drug Abuse.
Dr. Reggio is Marie Foscue Rourk Professor in the Department of Chemistry and Biochemistry, University of North Carolina Greensboro. In 2017 she was given to Academic Development Excellence Award from the North Carolina Biotechnology Center - Piedmont Triad and in 2010, she was awarded the Mechoulam Award for Outstanding Contributions to the Cannabinoid Field by the International Cannabinoid Research Society. She has an extensive portfolio of publications in peer reviewed journals, abstracts and book chapters. Dr. Reggio has served on a number of editorial and advisory boards including Cannabis and Cannabinoid Research, Commentary Editor and Endocannabinoid System Network Advisory Board for Sanofi-Aventis Pharmaceuticals.
A CPA with over 20 years of experience. David’s real-world experience includes over ten years with a Big 4 Public CPA firm and ten years working in various corporate positions including Director, Controller and CFO. David has help numerous companies with initial public offerings, reverse mergers, SEC compliance and mergers and acquisitions. David graduated from Benedictine University in Lisle, Illinois with a bachelor’s degree in accounting and became a CPA in 1994.
Secretary and Treasurer
JJ began as an advocate for cannabis over 20 years ago. He has been active in the education and cultivation of the Industry early in its development. Exploring the emerging industry of dispensing Medical Marijuana in Colorado, in 2008 he launched a MMJ Delivery Service in NW Colorado. This molded into a Brick & Mortar Retail location for Medical and Recreational Marijuana, with an Infused Product Manufacturer License & Large Grow Facility. In 2011, he launched a business focusing on the accessory market of the Cannabis Industry. For the last 6 years, he has co-owned Sand Gallery, Inc., a High-End Gallery, Glass-Blowing Studio, and Vape Shop. JJ focuses on the development of products in the cannabis space focused on the areas of branded, retail and medicinal areas of the industry.
Michael Beaubaire, M.D., to its Board of Directors.
Board of Directors
Dr. Beaubaire earned his BS with Honors in Finance from the Wharton School, and his BA with Honors in Biological Basis of Behavior from the College of Arts & Sciences, both at the University of Pennsylvania. He received his Medical Doctorate degree from Northwestern University Medical School, and trained as an Internal Medicine resident at Evanston Northwestern Healthcare where he served as an educator to medical interns and students under his tutelage
Judith Korner, M.D., Ph.D
Scientific Advisory Board
Dr. Korner received her medical degree at the College of Physicians and Surgeons of Columbia University where she also obtained her Ph.D. in Biochemistry and Molecular Biophysics in the laboratory of Dr. Richard Axel. She completed her internship and residency in Internal Medicine, served as Chief Medical Resident, and completed her fellowship in Diabetes, Endocrinology and Metabolism at Columbia University Medical Center.